Editas Medicine, Inc. (EDIT) Form 10-Q — Aug 5, 2026
Editas Medicine's Q2 2026 net loss narrowed 66% year over year to $18.2 million ($0.15 per share) from $53.2 million, as collaboration and R&D revenue jumped to $11.9 million from $3.6 million on recognition of deferred revenue from expiring BMS opt-in rights. Six-month revenue rose 79% to $14.7 million while six-month net loss fell 67% to $43.2 million. The company ended the quarter with $211.6 million in cash, equivalents and marketable securities after a May 2026 offering of 55.6 million shares with warrants that generated $125.0 million gross ($116.9 million net).
Key figures
- Revenue
- 11890000
- Total Debt
- 55738000
- Revenue Yoy
- +232% (Q2 2026 $11.9M vs Q2 2025 $3.6M); six-month revenue up 79% to $14.7M
- Total Assets
- 237364000
- Cash Position
- 211600000
- Shares Outstanding
- 153580035
- Cash runway
- into the second half of 2028
- Six month revenue
- 14721000
- Accumulated deficit
- 1671715000
- Warrants outstanding
- 55555556
- Atm remaining capacity
- 106100000
- Warrant exercise price
- 3.5
- May 2026 offering shares
- 55555556
- Atm gross proceeds to date
- 43900000
- May 2026 offering net proceeds
- 116900000
- Dri effective interest rate pct
- 7.7
- Operating lease future payments
- 17100000
- May 2026 offering combined price
- 2.25
- May 2026 offering gross proceeds
- 125000000
- Share count growth pct six months
- ~57% (97.9M at Dec 31, 2025 to 153.5M at Jun 30, 2026)
- Warrant potential additional proceeds
- 192500000
Price after filing
Close on the filing date to close N calendar days later (from $2.77). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.